Publications

1. GVS advice on mifepristone (Mifegyne®) for the treatment of miscarriages

   The National Health Care Institute has tested whether mifepristone (Mifegyne®) can be included in the Medicine Reimbursement ...

   Report | 08-03-2023

2. Conditional inclusion of orphan drugs, conditionals and exceptionals (progress report for 2022)

   At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...

   Report | 01-03-2023

3. Package advice on the lock procedure medicinal product trastuzumab-deruxtecan (Enhertu®) for the treatment of HER2-positive breast cancer

   The National Health Care Institute has assessed whether the medicinal product trastuzumab-deruxtecan (Enhertu®) can be reimbursed ...

   Publication | 15-02-2023

4. GVS advice icosapent-ethyl (Vazkepa®)

   The National Health Care Institute has completed its assessment whether the product icosapent-ethyl (Vazkepa®) can be included in ...

   Report | 15-02-2023

5. Package advice on the lock procedure medicinal product tafasitamab (Minjuvi®) for the treatment of lymphoma

   The National Health Care Institute has assessed whether the medicinal product tafasitamab (Minjuvi®) can be reimbursed from the ...

   Report | 15-02-2023

6. GVS advice patiromer (Veltassa®) cancellation List 2 conditions

   The Minister of Health, Welfare and Sport (VWS) has adopted the recommendation of the National Health Care Institute. This means ...

   Report | 01-02-2023

7. GVS advice empagliflozin (Jardiance®) extension List 2 conditions

   At the request of the Minister of Health, Welfare and Sport (VWS), The National Health Care Institute will assess whether the ...

   Report | 31-01-2023

8. GVS advice dexamethasone/levofloxacin eye drops (Ducressa®) for use by adults after cataract surgery

   The National Health Care Institute has assessed whether dexamethasone/levofloxacin (Ducressa®) can be included in the Medicine ...

   Report | 25-01-2023

9. GVS advice PCV15 (Vaxneuvance®) to prevent severe progression of pneumococcal disease in people in medical high-risk groups

   The National Health Care Institute has assessed whether the 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15, ...

   Report | 25-01-2023

10. GVS advice odevixibat (Bylvay®) for the treatment of progressive familial intrahepatic cholestasis

    The National Health Care Institute has assessed whether odevixibat (Bylvay®) can be included in the Medicine Reimbursement System ...

    Report | 18-01-2023